Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Equity Ratio (2018 - 2021)

Historic Equity Ratio for Black Diamond Therapeutics (BDTX) over the last 4 years, with Q3 2021 value amounting to 0.8.

  • Black Diamond Therapeutics' Equity Ratio fell 1547.08% to 0.8 in Q3 2021 from the same period last year, while for Sep 2021 it was 0.8, marking a year-over-year decrease of 1547.08%. This contributed to the annual value of 0.93 for FY2020, which is 41336.53% up from last year.
  • Black Diamond Therapeutics' Equity Ratio amounted to 0.8 in Q3 2021, which was down 1547.08% from 0.87 recorded in Q2 2021.
  • Over the past 5 years, Black Diamond Therapeutics' Equity Ratio peaked at 0.98 during Q2 2020, and registered a low of 0.3 during Q4 2018.
  • For the 4-year period, Black Diamond Therapeutics' Equity Ratio averaged around 0.65, with its median value being 0.9 (2021).
  • As far as peak fluctuations go, Black Diamond Therapeutics' Equity Ratio soared by 41336.53% in 2020, and later plummeted by 1547.08% in 2021.
  • Quarter analysis of 4 years shows Black Diamond Therapeutics' Equity Ratio stood at 0.3 in 2018, then rose by 0.66% to 0.3 in 2019, then surged by 413.37% to 0.93 in 2020, then fell by 14.44% to 0.8 in 2021.
  • Its Equity Ratio was 0.8 in Q3 2021, compared to 0.87 in Q2 2021 and 0.9 in Q1 2021.